Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem announced today that the Food & Drug Association (FDA) has granted both orphan drug and fast track designation to ANG1005 a novel paclitaxel-peptide drug conjugate leveraging the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer, for the treatment of glioblastoma multiforme (GBM).

31 May 2014

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.

31 May 2014

New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center.

28 May 2014

Sorrento Therapeutics prices underwritten public offering of 4,765,000 shares of common stock

Sorrento Therapeutics, Inc. ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share.

15 May 2014

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

A study which will be published in the May 2014 issue of Experimental Biology and Medicine was aimed at determining whether an EGFR-targeted therapy combined with chemo-radiotherapy can improve local tumor control effectively, compared to cytotoxic agents or irradiation alone.

14 May 2014

Verastem announces expansion of ongoing COMMAND study in Japan

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the expansion of its ongoing COMMAND study to include clinical trial sites in Japan.

12 May 2014

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Kinex Pharmaceuticals, Inc. announced today that the United States Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for Oratecan, an oral form of an approved anti-cancer drug irinotecan with enhanced oral absorption.

6 May 2014

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Effects of PectaSol-C modified citrus pectin in prostate cancer patients to be studied in phase III trial

A phase III clinical trial conducted at the Meir Medical Center in Kfar-Saba, Israel is now recruiting participants to study the effects of dietary supplement PectaSol-C modified citrus pectin (MCP) in controlling prostate specific antigen (PSA) levels in prostate cancer patients.

15 Apr 2014

Inhibiting cancer-promoting prolactin causes unconventional cell death in preclinical research

Under stress from chemotherapy or radiation, some cancer cells dodge death by consuming a bit of themselves, allowing them to essentially sleep through treatment and later awaken as tougher, resistant disease.

4 Apr 2014

Tgen professor to receive 2014 Hope Funds Award for developing numerous cancer treatments

Dr. Daniel D. Von Hoff, who has been instrumental in developing numerous new cancer treatments, is among this year's recipients of the Award of Excellence from the Hope Funds for Cancer Research.

28 Mar 2014

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

11 Mar 2014

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

In association with its 50th anniversary, the American Society of Clinical Oncology has named Dr. Daniel D. Von Hoff one of ASCO's 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care.

9 Mar 2014

Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced solid tumors, including one patient with mesothelioma. The Phase 1 study assessed the safety and pharmacokinetics of single agent VS-6063.

5 Mar 2014

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.

28 Feb 2014

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

Adding motesanib to carboplatin/paclitaxel significantly improves overall survival in Asian patients with nonsquamous non-small-cell lung cancer compared with carboplatin/paclitaxel alone, researchers report.

27 Feb 2014

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera presented results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) this past weekend to top clinicians and scientists at the invitation-only International Association for the Study of Lung Cancer meeting on targeted therapies in Santa Monica, CA.

26 Feb 2014

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Non-small-cell lung cancer patients with very unusual epidermal growth factor receptor mutations may be more likely to be benefit from first-line chemotherapy than a tyrosine kinase inhibitor, research suggests.

25 Feb 2014

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014